PL2225261T3 - Inhibitory boropeptydowe enteropeptydaz i ich zastosowania w leczeniu otyłości, nadwagi i/lub chorób związanych z nieprawidłowym metabolizmem tłuszczów - Google Patents

Inhibitory boropeptydowe enteropeptydaz i ich zastosowania w leczeniu otyłości, nadwagi i/lub chorób związanych z nieprawidłowym metabolizmem tłuszczów

Info

Publication number
PL2225261T3
PL2225261T3 PL08855879.6T PL08855879T PL2225261T3 PL 2225261 T3 PL2225261 T3 PL 2225261T3 PL 08855879 T PL08855879 T PL 08855879T PL 2225261 T3 PL2225261 T3 PL 2225261T3
Authority
PL
Poland
Prior art keywords
enteropeptidase
overweight
obesity
treatment
diseases associated
Prior art date
Application number
PL08855879.6T
Other languages
English (en)
Inventor
Itzik Harosh
Sandrine Braud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2225261T3 publication Critical patent/PL2225261T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043Leu-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • C07K5/06095Arg-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06104Dipeptides with the first amino acid being acidic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • C07K5/0817Tripeptides with the first amino acid being basic the first amino acid being Arg
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0827Tripeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL08855879.6T 2007-12-03 2008-12-03 Inhibitory boropeptydowe enteropeptydaz i ich zastosowania w leczeniu otyłości, nadwagi i/lub chorób związanych z nieprawidłowym metabolizmem tłuszczów PL2225261T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99673207P 2007-12-03 2007-12-03

Publications (1)

Publication Number Publication Date
PL2225261T3 true PL2225261T3 (pl) 2016-09-30

Family

ID=40404110

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08855879.6T PL2225261T3 (pl) 2007-12-03 2008-12-03 Inhibitory boropeptydowe enteropeptydaz i ich zastosowania w leczeniu otyłości, nadwagi i/lub chorób związanych z nieprawidłowym metabolizmem tłuszczów

Country Status (11)

Country Link
US (2) US20100311690A1 (pl)
EP (1) EP2225261B1 (pl)
CA (1) CA2707549A1 (pl)
DK (1) DK2225261T3 (pl)
ES (1) ES2575131T3 (pl)
HR (1) HRP20160569T1 (pl)
HU (1) HUE028064T2 (pl)
PL (1) PL2225261T3 (pl)
PT (1) PT2225261E (pl)
SI (1) SI2225261T1 (pl)
WO (1) WO2009071601A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2511271T3 (pl) 2009-12-07 2015-06-30 Ea Pharma Co Ltd Pochodna estru kwasu heteroarylokarboksylowego
ES2618024T3 (es) 2011-06-07 2017-06-20 Ea Pharma Co., Ltd. Derivado de éster de ácido carboxílico heterocíclico
EP2852678B1 (en) 2012-05-22 2017-08-23 Biogen MA Inc. Trapping reagents for reactive metabolites screening
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
SG10201707504VA (en) 2013-03-13 2017-10-30 Takeda Pharmaceuticals Co Guanidinobenzoic acid ester compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2016100555A1 (en) * 2014-12-18 2016-06-23 Inception 4, Inc. Boronic acid derivatives and uses thereof
US9975903B2 (en) 2014-12-26 2018-05-22 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
EP3246394B1 (en) 2015-01-15 2022-11-23 Osaka University Method for inducing differentiation of corneal epithelial cells from pluripotent stem cells
JP6634070B2 (ja) 2015-03-27 2020-01-22 武田薬品工業株式会社 縮合複素環化合物
PL3472149T3 (pl) 2016-06-21 2024-02-12 Orion Ophthalmology LLC Heterocykliczne pochodne prolinamidu
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
BR112020008676A2 (pt) 2017-11-02 2020-10-27 Ube Industries, Ltd. composto, e, composição farmacêutica.
GB201809378D0 (en) * 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2021013742A1 (en) 2019-07-19 2021-01-28 Janssen Pharmaceutica Nv 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase
CN115252758A (zh) * 2022-08-16 2022-11-01 中国科学院南海海洋研究所 线性小分子肽类似物在制备抗肥胖和降糖药物中应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867539A (en) 1973-04-27 1975-02-18 Us Health Method of producing anorexia as a treatment for obesity
US4446138A (en) 1982-02-10 1984-05-01 Pack Howard M Method and composition for reducing weight
US4588724A (en) 1982-12-10 1986-05-13 Greenway Frank L Iii Treatment for selective reduction of regional fat deposits
GB8430581D0 (en) 1984-12-04 1985-01-09 Ferrosan As Treatment
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5019594A (en) 1989-11-28 1991-05-28 Interneuron Pharmaceuticals, Inc. Method for decreasing appetite
US5300298A (en) 1992-05-06 1994-04-05 The Pennsylvania Research Corporation Methods of treating obesity with purine related compounds
US5573774A (en) 1993-02-02 1996-11-12 Keenan; Robert M. Nicotine metabolites, nicotine dependence and human body weight
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US5578613A (en) 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
SE9403861D0 (sv) 1994-11-09 1994-11-09 Astra Ab Novel medicinal use
FR2745288B1 (fr) * 1996-02-27 1998-04-17 Adir Nouveaux derives de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA001539B1 (ru) 1996-11-27 2001-04-23 Пфайзер Инк. Амиды, ингибирующие секрецию аполипопротеина в (аро в) и/или микросомного протеина переноса триглицеридов (мтр)
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
CA2588087A1 (en) * 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat

Also Published As

Publication number Publication date
CA2707549A1 (en) 2009-06-11
WO2009071601A1 (en) 2009-06-11
HUE028064T2 (en) 2016-11-28
SI2225261T1 (sl) 2016-07-29
PT2225261E (pt) 2016-06-09
US20140187479A1 (en) 2014-07-03
EP2225261B1 (en) 2016-03-09
US9481709B2 (en) 2016-11-01
ES2575131T3 (es) 2016-06-24
US20100311690A1 (en) 2010-12-09
HRP20160569T1 (hr) 2016-07-29
DK2225261T3 (en) 2016-06-06
EP2225261A1 (en) 2010-09-08

Similar Documents

Publication Publication Date Title
SI2225261T1 (sl) Boropeptidni inhibitorji enteropeptidaze in njihove uporabe pri zdravljenju debelosti, prekomerne teže in/ali bolezni, povezanih z nenormalno presnovo maščob
EP2150308A4 (en) ANALYSIS AND REGULATION OF FOODSTUFFS
ZA200905101B (en) Diagosis and treatment of preeclampsia
PT1945235E (pt) Probióticos para influenciar o metabolismo da gordura e a obesidade
GB2465677B (en) Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes
GB2439393B (en) Cannabinoids for use in the treatment of neuropathic pain
IL197568A0 (en) Treating pain, diabetes, and disorders of lipid metabolism
EP2229209A4 (en) IV CATHETER WITH ONLINE VALVE AND ASSOCIATED METHODS
IL208518A0 (en) Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
EP2317845A4 (en) METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON
ZA201003497B (en) Methods for treating obesity and obesity related diseases and disorders
IL209666A0 (en) Gip-based mixed agonists for treatment of metabolic disorders and obesity
PL2514436T3 (pl) IL-22 do zastosowania w leczeniu schorzeń drobnoustrojowych
SI2254870T1 (sl) 1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1, CX3CR1
ZA201101213B (en) Compositions and methods for treating disorders associated with overweight animals
EP2142664A4 (en) ESTIMATION AND BIOLOGICAL CONSEQUENCES OF OXIDATIVE METABOLISM
GB0619860D0 (en) Treatment of insulin resistance and disorders associated therewith
ZA201202151B (en) Compositions comprising tramadol and celecoxib in the treatment of pain
IL207278A0 (en) 1 - benzyl - 3 - hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp - 1, and cx3cr1
PL2645878T3 (pl) Zapobieganie lub leczenie nadwagi i otyłości u pacjentów z cukrzycą typu 2
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
EP1987826A4 (en) MEDICAMENT AND FUNCTIONAL FOOD TO COMBAT OR PREVENT JUCKREIZ AND IGNITION
PT2475361T (pt) Derivados de benzenopropanamidas substituídas em n, para serem utilizadas no tratamento de dor e de inflamação
WO2011028881A9 (en) Methods and implants for inducing satiety in the treatment of obesity
ZA200904755B (en) Use of epothilones in the treatment of osteoporosis and related diseases